国会预算办公室：2022年和解法案药物条款的影响：到目前为止我们学到了什么，还有什么问题？（英文版）

This presentation reviews how CBO estimated the budgetary effects of three provisions of the 2022 reconciliation act related to prescription drugs: drug price negotiation in Medicare, the Medicare inflation rebate, and the redesign of the Medicare Part D benefit. CBO describes how recent developments affect the agency's assessment of the effects of each of those provisions and poses unanswered questions for which the agency would like the panel members' insights. CBO also comments on its